Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Bevacizumab vs Dacarbazine in Metastatic Melanoma

This study has suspended participant recruitment.
(Lack of financing of the study drug. Not sufficient financial support.)
Sponsor:
Collaborators:
The Norwegian Melanoma Group
Norwegian Cancer Society
Information provided by (Responsible Party):
Haukeland University Hospital
ClinicalTrials.gov Identifier:
NCT01705392
First received: October 8, 2012
Last updated: September 9, 2015
Last verified: September 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: June 2018
  Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)